Discovered a Future Therapeutic Target for Lung Cancer Treatment
News Jul 22, 2013
Two recent examples in this field are the findings that lung cancer patients carrying mutations in EGFR and ALK are more sensitive to certain drugs with tyrosine kinase inhibitory activity. The problem is that few cancer patients show the aforementioned genetic defects susceptible to be treated with the new drugs.
The magazine Oncogene has published an article ed by Manel Esteller, Director of Epigenetics and Cancer Biology Biomedical Research Institute (IDIBELL), ICREA researcher and Professor of Genetics at the University of Barcelona, which describes a new genetic alteration an oncogene in lung cancer that could be a good candidate for the development of specific drugs.
"We found that in 5-10% of lung tumors, instead of having normal dose of oncogene (two copies, one on the maternal chromosome and one on the paternal) have an overdose of it, about 10 copies gene pool "explained Manel Esteller, director of the study.
The new identified oncogene originates the protein called SETDB1, a histone methyltransferase. It is an enzyme which can be inhibited by compounds in which drug industry has experience.
"Our study," explained Esteller "indicates a weakness of the defensive wall of the tumor cell and it has been possible to detect through the European project CURELUNG . Now we would like some pharmaceutical company follow this line of research in the future availability of an applicable drug in patients".
Duplicate Genes Offer a Explanation for Differences Between the SexesNews
A study in flies has identified the process by duplicating a gene can help resolve genetic sexual conflict.READ MORE
Pre-Clinical Safety in Cancer Drug Development: “Attitude to Safety Needs to Change”News
Many companies involved in cancer drug research and development need to re-think their use of safety data in helping to bring new drugs to cancer patients.
Dr Richard Knight of ApconiX will tell this month’s conference, that greater focus on pre-clinical safety should be fundamental to the development of new cancer therapies.
Understanding the Process of Cell DivisionNews
Using multiple techniques such as structural modelling, X-ray scattering, X-ray crystallography and electron microscopy, scientists have found that the Spc110 protein provides a greater function in mitosis originally believed. This information could help understand the process in human cells and the abnormalities that occur in cancer.READ MORE